IMUX241220C2500
- 0.04
- 0.000.00%
Immunic Newsroom
Analysts' Opinions Are Mixed on These Healthcare Stocks: Adaptimmune Therapeutics (ADAP), Fulcrum Therapeutics (FULC) and Immunic (IMUX)
Insider Buys Additional US$100k In Immunic Stock
Immunic Announces Publication of IMU-856 Data
Immunic Reports Positive Phase 1 Results for Celiac Disease Therapy Published in The Lancet | NASDAQ:IMUX
Express News | Immunic Announces Publication of Data From Phase 1/1B Clinical Trial of Imu-856 in the Peer Reviewed Journal, the Lancet Gastroenterology & Hepatology
Optimistic Buy Rating for Immunic Driven by Promising Trials and Market Opportunities for VidoCa
Immunic, Inc. (IMUX) Q3 2024 Earnings Call Transcript Summary
Immunic, Inc. Advances MS Trials Amid Financial Update
Express News | EF Hutton Maintains Buy on Immunic, Maintains $17 Price Target
Immunic Analyst Ratings
Immunic CEO Details Progress Following Productive Third Quarter | NASDAQ:IMUX
Immunic | 10-Q: Q3 2024 Earnings Report
Immunic | 8-K: Immunic, Inc. Reports Third Quarter 2024 Financial Results and Provides Corporate Update
Immunic: Q3 Earnings Snapshot
Express News | Immunic's Cash And Cash Equivalents As Of September 30, Were $59.1M, Expected To Provide Cash Runway Into Q3 Of 2025
Express News | Immunic Q3 2024 GAAP EPS $(0.24) Misses $(0.22) Estimate
Express News | Immunic Q3 Income From Operations USD -25.726 Million
Immunic 3Q Loss/Shr 24c >IMUX
Immunic 3Q Loss $24.4M >IMUX
Immunic, Inc. Reports Third Quarter 2024 Financial Results and Provides Corporate Update